Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
Date:10/28/2008

s the most widely used type of delivery-system because it provides physicians additional flexibility to work as single operators during stent procedures.

XIENCE V was launched in Europe and other international markets in October 2006 and is an investigational device in Japan where it is currently under review by the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its antiproliferative properties.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at http://www.xiencev.com.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
2. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
3. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
4. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
5. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
6. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
7. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
8. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
10. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
11. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 ... the addition of the "Spectroscopy Equipment ... report to their offering. ... for Spectroscopy Equipment and Accessories in US$ ... Spectroscopy (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, ...
(Date:8/19/2014)... 19, 2014   Synthetic Biologics, Inc. ... anti-infective biologic and drug programs targeting specific pathogens ... that its novel C. difficile development ... Interscience Conference on Antimicrobial Agents and Chemotherapy ... Synthetic Biologics, Senior Vice ...
(Date:8/18/2014)... 2014 Deep Research Report on Global ... in-depth research report on the China Linalool market. ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... environment & economic situation analysis. The report on ...
(Date:8/18/2014)... , Aug. 18, 2014 ... of advanced consumer medical devices said that ... was interviewed by CEOLIVE.TV as part of ... entire interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... Kotak explains to investors the unique advantages ...
Breaking Biology Technology:Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... WALTHAM, Mass. , June 2 Repligen Corporation (Nasdaq: RGEN ... quarter and fiscal year 2010, on Wednesday, June 9th, 2010 , before ... Herlihy , Ph.D., will host a conference call and webcast on the same ... provide a quarterly update on the Company. , ...
... June 2 Vermillion, Inc. (Pink Sheets: VRML), ... Patent Office has issued a Decision to Grant patent ... Cancer" to the Company. The patent claims are directed ... ovarian cancer and to the measurement of the biomarkers ...
... ... The iuvo™ Chemotaxis Assay ( http://www.bellbrooklabs.com/iuvo_chemotaxis_assay_plate.html ) Plate ... measurements of neutrophil chemotaxis ( http://www.bellbrooklabs.com/iuvo_chemotaxis_assay_plate.html ) in a ... time period of the assay. Designed for use ...
Cached Biology Technology:Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 3Vermillion Announces Issuance of European Patent 2Vermillion Announces Issuance of European Patent 3BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient 2BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient 3BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient 4
(Date:8/20/2014)... Carolina State University researchers have developed methods for electronically ... the electrical signals moths use to control those muscles. ... remotely-controlled moths, or "biobots," for use in emergency response. ... whether we can control the movement of moths for ... says Dr. Alper Bozkurt, an assistant professor of electrical ...
(Date:8/19/2014)... be made to decrease China,s increasing caesarean section rate, ... BJOG: An International Journal of Obstetrics and Gynaecology ... caesarean delivery rates in the world. Of 16 million ... Although the exact rate is not known, the current ... total caesarean rates ranging from 36% to 58%. However, ...
(Date:8/19/2014)... Long-Term Ecological Research and Network-Level Science, , Imagine if ... range of ecosystems was responding to global changes in ... if it coupled multiple decades of information about ecological ... models from dozens of different ecosystem types. , ... Ecological Research (LTER) Network, which will soon celebrate its ...
Breaking Biology News(10 mins):Research paves way for development of cyborg moth 'biobots' 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3This week from AGU: Long-term ecological research, predicting cholera outbreaks 2
... Not all trans fats are created equal and it,s time ... reflect this, particularly when it comes to dairy and beef ... the latest edition of Advances in Nutrition , natural ... beef cattle are not detrimental to health and in fact ...
... team of leading marine scientists from around the world ... the deep sea, the Earth,s largest ecosystem. Instead, ... consumers., In a comprehensive analysis published online this week ... fisheries biologists, economists, mathematicians and international policy experts show ...
... fared better than other non-advanced technology exports during the recent ... Foundation (NSF). NSF,s National Center for Science and Engineering ... 2008 to $245 billion in 2009. But this 9 ... ATP exports. ATP exports embody new or leading edge ...
Cached Biology News:Time to reboot thinking on trans fats -- natural trans fats from dairy and beef are good 2Deep-sea fish in deep trouble 2Deep-sea fish in deep trouble 3Recent trends show recession's effect on US advanced technology exports 2
... produced by a patented microwave process which ... consistent, even cell attachment, increased cell growth ... growth uunder difficult conditions, including reduced serum ... a more ecominic alternative to expensive and ...
...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
... Lines ,High Quality, Functionally-Validated, Ion Channel Cell ... for having a critical role in nerve ... key function in pain, CNS and the ... been investigated in therapeutic areas, such as ...
Biology Products: